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Endoscopic Dilatation of Dominant Strictures
in Primary Sclerosing Cholangitis
ABSTRACT
Wagner, S.,, Gebel, M.,, Meier, P.,, Trautwein, C.,, Bleck,
J.,, Nashan, B., and Manns, M. P., (1996) Endoscopic
Management of Biliary Tract Strictures in Primary
Sclerosing Cholangitis. Endoscopy; 28: 546-551.
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PAPER DISCUSSION
Background and Study Aims: In a subgroup of
patients, primary sclerosing cholangitis (PSC) is
complicated by high-grade focal strictures of the bile
ducts, and this can have an unfavourable influence
on the natural course of the disease. The aim of this
study was to evaluate the efficacy and safety of
endoscopic treatment in this selected patient group.
Patients and Methods: Twelve symptomatic patients
with primary sclerosing cholangitis and major ductal
strictures were included in a prospective study of
endoscopic treatment. All patients were managed by
repeated angioplasty-type balloon dilation and na-
sobiliary catheter perfusion. A minimum of two
treatment sessions was used, and therapy was
continued until satisfactory reopening of the stric-
tures was obtained. Routine endoscopic follow-up
was performed after three, six, 12,18, and 24 months,
and then at yearly intervals. The efficacy of therapy
was assessed by evaluating clinical symptoms,
laboratory data, and cholangiograms.
Results: The long-term follow-up averaged 23
months (range: 12-50 months). Two to nine (mean:-
three) treatment sessions were required to obtain
satisfactory reopening of major biliary strictures.
Eight patients showed considerable and sustained
improvement. The mean serum bilirubin, alkaline
phosphatase, -y-glutamyl-transpeptidase, and alanine
aminotransferase levels fell significantly by 73% (P=
0.0164), 46% (P= 0.0022), 55% (P=0.0022), and 58%
(P=0.0022), respectively. The average radiographic
stricture score before treatment was 3.2 4-0.7 (mean
4-SD), and after treatment decreased to 1.9 4- 0.8 (P=
0.0033). Three patients required liver transplantation
seven, 12, and 40 months after the initiation of
endoscopic treatment, due to a deterioration in
hepatic function or an inability to exclude complex
biliary malignancy. No major procedure-related side
effects were observed.
Conclusions: Our results suggest that the endo-
scopic treatment of PSC patients with dominant
bile duct strictures is effective, safe, and well-
tolerated. However, it is important not to overlook
the potential development of cholangiocarcinoma.
The paper by Wagner et al., reviewed the results
of endoscopic treatment in twelve symptomatic
patients with primary sclerosing cholangitis
(PSC) complicated by dominant strictures of
the extrahepatic bile ducts. Combining nasobili-
ary catheter perfusion and repeated balloon
dilations, they demonstrated improvement in
clinical, biochemical, and radiological para-
meters during a mean follow-up period of 23
months (range 12-50 months). Importantly,
endoscopic therapy resulted in a significant
drop in serum bilirubin levels, and septic
complications following ERCP were minimal.
Three patients required liver transplantation for
progression to endstage liver failure or sus-
pected complicating cholangiocarcinoma.
Although PSC usually affects the biliary tree
diffusely, some patients have high-grade stric-
tures of the extrahepatic biliary tree, often near
or at the hepatic duct bifurcation [1], and where
the cystic duct enters the bile duct. The term
"dominant stricture" is imprecise, and may
include any "flow limiting" stricture involving
the extrahepatic biliary tree, even though it
might not necessarily be the most severe
stricture [2]. Some authors have recommended
resection and/or bypass of the hepatic duct
bifurcation for selected patients with advanced
PSC and a dominant stricture who have devel-
oped persistent jaundice but who do not have
cirrhosis [2, 3]. However, major surgery may
compromise future transplant and the risk for
the development of cholangiocarcinoma remainsHPB INTERNATIONAL 69
[4, 5]. Furthermore, the presence of a dominant
stricture on cholangiography has not been
shown to be an independant predictor of
survival in the various prognostic models that
have been developed for PSC using multivariate
analysis [6]. It is now generally accepted that
patients with advanced PSC should proceed
directly to transplant and that palliative surgical
operations should be avoided.
Should endoscopic therapy be recommended
for patients with advanced PSC and dominant
strictures of the extrahepatic bile ducts? This
form of treatment is theoretically appealing in
PSC as it is much less invasive than biliary
surgery, the biliary anatomy is not interfered
with, treatments may be repeated, and biliary
brushings can be taken for cytology. The results
after endoscopic therapy would only need to be
as good as (and not better than) those of surgical
drainage/bypass operations for this to become
the preferred mode of therapy for PSC and
dominant strictures. However, the caveats for
surgical and endoscopic therapy are essentially
the same. In this study, half of the patients were
cirrhotic. Biopsy was only performed "if indi-
cated", so this figure may be an underestimate of
the actual number of cirrhotic patients. We would
caution against any biliary manipulations in PSC
patients with endstage biliary cirrhosis, as the
injection of contrast into a poorly drained biliary
system may set up a vicious cycle of biliary sepsis
and further interventional procedures, and the
patient may forego the chance of a transplant due
to uncontrolled sepsis. The endoscopic therapy
given was also not minimally invasive: following
initial ERCP, all patients in the study received
saline perfusion of the biliary tree via a nasobili-
ary tube for a week, and up to nine (average
three) ERCP sessions were required to achieve a
satisfactory cholangiographic result. Neverthe-
less, nasobiliary perfusion maybe important, and
might have been a reason for the low incidence of
biliary sepsis noted in this study.
It is particularly difficult to study the effect of
endoscopic treatment, or for that matter any
therapy, on the course PSC for a number of
reasons: (1) PSC is uncommon (but not rare, as
previously thought); (2) its course is variable
albeit slowly progressive over many years; and
(3) there is the unpredictable occurrence of
cholangiocarcinoma. Furthermore, only a small
subgroup of patients with PSC have dominant
strictures (12/41 patients or 29% in this series).
Single institution series invariably have small
numbers of patients and it is therefore not
possible to randomise treatment groups in a
controlled study. Patients may also be receiving
other therapies that could affect the outcome,
and in this study all patients were continued on
ursodeoxycholic acid and were given intrave-
nous ciprofloxacin for a week following ERCP.
Follow-up is usually over months and not
several years. Despite these inherent problems
which bedevil all PSC treatment studies, pa-
tients in this study seemed to benefit from
endoscopic therapy, and the marked reduction
in serum bilirubin levels was particularly en-
couraging. Serum bilirubin levels are probably
the single most important predictor of outcome
in PSC, and features in all prognostic models.
However it has not been shown that interven-
tions that reduce the serum bilirubin level have a
favourable effect on prognosis, and three pa-
tients in this series required liver transplantation.
Of greater concern however is the unpredict-
able occurrence of cholangiocarcinoma which
may arise in about 10-20% of PSC patients.
Features suggestive of a complicating cholan-
giocarcinoma include rapid clinical deterioration
in a patient with previously stable PSC, and
progressive stricturing and duct dilatation on
cholangiography. The presence of a high grade
dominant stricture must always raise the suspi-
cion of cholangiocarcinoma, and repeated biliary
brushings may be required to detect malignant
cells. Although no patient in this study devel-
oped cholangiocarcinoma, the follow-up may
not have been long enough to detect this
devastating complication. Unfortunately, there
is currently no reliable way of predicting which70 HPB INTERNATIONAL
patients with PSC will develop a cholangiocar-
cinoma. Screening tests (serum tumour marker
CA 19-9 and CEA, and cytology of biliary
brushings) are only helpful in a negative sense,
i.e., patients found to have cholangiocarcinoma
are excluded from transplant. There thus seems
little justification in delaying liver transplanta-
tion in young symptomatic patients with ad-
vanced PSC and dominant strictures.
Liver transplantation for PSC has problems of
its own, and there appears to be a higher
complication rate following tranplantation for
PSC than for other diseases causing end-stage
liver failure, in particular a higher rate of biliary
stricturing in the transplanted ducts [7]. Possible
causes of the strictures include recurrent PSC,
ischaemic bile duct injury, chronic ductopaenic
rejection, and infectious cholangitis related to
the Roux-en-Y anastomosis and immunosup-
pression. However, three year survival after
liver transplantation for PSC is 85% at most
centres [7]. Furthermore, it is the only treatment
that removes the risk of cholangiocarcinoma in
PSC (the risk for colonic carcinoma in patients
with co-existing ulcerative colitis however re-
mains). We would reserve the use of biliary
dilatation for the small subgroup of patients
with early PSC and a dominant stricture invol-
ving the distal bile duct. PSC is usually a diffuse
disease of the biliary tree not amenable to local
therapy and, in this enigmatic condition, it is
particularly important to treat the patient and
not the cholangiogram. Furthermore, endoscopic
therapy for PSC may be technically very
demanding, and should only be performed at a
centre of endoscopic excellence with transplan-
tation facilities, such as that of Professor Manns
in Hanover.
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